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INTRODUCTION
Schizophrenia is a heterogeneous disorder with a worldwide lifetime prevalence among adults near 1% [1, 2] . The illness typically debuts in late adolescence or young adulthood, can affect personal, educational, social, and vocational skills, and ranks among the 20 leading global causes of disability worldwide [3] . Fortunately, and based on recent evidence, the conceptualization of illness outcome has progressively evolved to a more optimistic and inspiring perception of the illness with an expectation of functional recovery from the first episode [4, 5] . Imaging, clinical, and cognitive longitudinal data do not support the notion of a deteriorating course of the illness [6-10], which consequently raises legitimate expectations of living a normal life with mental illness. Systematic reviews of outcome studies have reported that 40-42% of people with a first episode of psychosis (FEP) have a good outcome [11, 12] , although when more stringent criteria of functional recovery are used the rate drops to 13.5% long term [13] . Schizophrenia is unquestionably a potentially disabling and severe mental illness;
however, an appropriate multidisciplinary and integrated treatment approach from the first episode can make a fulfilling and productive life and the achievement of full potential possible in spite of the limitations caused by the illness.
''Recent-onset psychosis'' has been previously proposed as a more accurate term for referring to individuals who have experienced a short duration of illness (e.g., 2-5 years) [14] . By contrast, the term ''first episode psychosis '' may include all subjects with a first treatment contact, independently of the duration of the symptoms. It has been stated that there is a critical period of 2-5 years following onset of psychosis during which future trajectories of functional outcome may be set and when interventions are likely to have a maximum beneficial effect [15] . Recovery from a FEP has come into focus as the main goal of any treatment strategy. Many changeable factors such as clinical (medication adherence, treatment response) and psychotherapeutic treatments, psychoeducation about the illness, therapeutic alliance, support and recognition of the needs of the people with a FEP and carers, societal stigma, substance misuse, social and family support, and physical health may affect reaching this functional status [16] . Preventing relapse in the early stages of disease has become a major challenge due to its critical impact on life-long functionality [17] . Non-adherence to antipsychotic treatment and lack of insight into the illness are very frequent in people with a FEP [18] . Poor adherence to treatment is associated with an increased rate of relapse [19, 20] . Lack of insight promotes non-adherence to medication and leads to a poorer course of illness and functioning [21] [22] [23] . Either because clinicians are not always fully aware of these notions or because these ideas are not well understood and accepted by people in the early stages of the illness, achieving and maintaining good adherence to the prescribed treatment is a major clinical issue.
Implementing the most suitable treatment strategies and making appropriate clinical decisions about individuals with a FEP is a complex and crucial task, with associated impact on illness outcome. These beneficial effects seem to be more pronounced for those patients who received the proper comprehensive specialty care as early as possible in the course of the illness [24] . A number of previous publications have reviewed early intervention models or specific issues (i.e., side effects of antipsychotics or long-acting injectable antipsychotics) in the treatment of people with a FEP. However, there is a lack of updated reviews of the pharmacological treatment of people with a FEP, including use of novel antipsychotics that help clinicians to choose and manage these medications. This article aims to provide clinicians with practical recommendations on how best to manage people with a FEP. The selection of an antipsychotic in the first stage of the illness could be a highly relevant decision, with a direct impact on adherence to medication and acceptance of the illness, and therefore influence the course and the outcome of the illness. Advantages and disadvantages of currently widely used drugs to treat schizophrenia are outlined and discussed.
METHODS
To obtain a fuller picture of the current best treatment of people with a first episode of non-affective psychosis a literature search (1966 up The review is based upon studies carried out with adults as well as children and adolescents.
We attempted to identify additional studies through searches of the reference lists of identified studies and reviews. Relevant data obtained from articles based on chronic schizophrenia samples were clearly identified and separately reported to avoid any misleading literature on first episode subjects.
This article is based on previously conducted studies and does not encompass new studies of human or animal subjects performed by any of the authors.
AIMING FOR EFFICACY AND EFFECTIVENESS
Balancing risks and benefits of antipsychotic agents and, subsequently, increasing the likelihood of adherence to treatment is the real challenge in the treatment of FEP individuals [25] . Table 1 summarizes the   advantages  and  disadvantages  of  the antipsychotic agents discussed in this review. The initial better tolerability of SGAs based on the diminished emergence of extrapyramidal [26, 27] . Presently it is widely accepted that there is not an obvious 
CARDIOMETABOLIC SIDE EFFECTS: SILENT LONG-TERM DAMAGE
In deciding among therapeutic options, 
Weight Gain
The first months of antipsychotic treatment represent the critical period for changes in weight [61, 62] . Longitudinal studies in drug-naïve subjects have shown that the percentage of obese (body mass index (BMI) [30) subjects increased from 5% to 32% and the percentage of overweight rose up to 65% at 3 years after the initiation of treatment with olanzapine, risperidone, or haloperidol [62] . switching from treatments with a high risk of weight gain to ziprasidone [70, 71] or to aripiprazole [72] is an effective strategy to reduce weight and improve metabolic outcomes in people with stable chronic schizophrenia or schizoaffective disorder. Finally, short-term, double-blind clinical trials comparing ziprasidone with placebo parameters [73, 74] or aripiprazole with placebo [75] in people with chronic schizophrenia or schizoaffective disorder have not found significant differences in their effects on metabolic variables.
The severity of weight increase, and therefore fatty change, is correlated with hepatic and cardiovascular toxicity. Thus, obesity is a risk factor for nonalcoholic fatty liver disease (NAFLD), which is the most common cause of liver disease in Western countries [76] . Overall, it has been described that 50% of people with a [77] . It has been observed that individuals treated with olanzapine who gained a substantial amount of weight manifested significantly lower heart rate variability (a marker of high cardiovascular risk) [78] .
In addition to physical disturbances, weight stigmatization and discrimination lead to important psychological stress that increases the risk for depression, low self-esteem, and body dissatisfaction in people with schizophrenia [79] . In the long term, weight gain may lead to poorer social and functional outcomes [80] and weight loss is linked to an improvement in social functioning [81] in people with schizophrenia.
Behavioral and counseling interventions including smoking cessation, dietary measures, and exercise might be partly effective in reducing weight gain and metabolic disturbances in early stages of treatment [82] [83] [84] . Nonetheless, the benefits of these lifestyle interventions do not seem to persist across time [85] . The preferential use of or switching to medications with a lower risk of weight and/or metabolic abnormalities is recommended [86] .
Glucose Metabolism
The risk of glucose intolerance and diabetes associated with antipsychotic treatments seems to be increased in younger subjects [87] . After 3 years of antipsychotic treatment, insulin plasma levels and the HOMA index tend to increase in FEP individuals [62] . Olanzapine, clozapine, and quetiapine have been associated with more prevalent hyperglycemia independently of body mass in both drug-naïve [88] and chronic schizophrenia individuals [89, 90] . Higher levels of insulin and insulin resistance were associated with olanzapine treatment in patients with FEP or schizophrenia and in healthy normal-weight men [31, 91, 92] . Quetiapine treatment has also been shown to increase the risk of triglycerides to HDL-C ratio (a marker of insulin resistance) in FEP [50] . A critical factor to bear in mind by clinicians is the fact that type 2 diabetes might have an onset a median of 4 years after first antipsychotic treatment, although subjects on olanzapine had a shorter time to diabetes onset [88] . It has also been reported that olanzapine discontinuers did not have an increased risk of diabetes [88] . Higher antipsychotic dosages and male sex seem to be related to an increased risk for diabetes. Due to the close association between metabolic effects and the greater risk of diabetes, pre-diabetes or type 2 diabetes should be prevented or postponed by choosing as a first choice an antipsychotic with a lower cardiometabolic burden.
Lipid Metabolism
After 3 years of antipsychotic treatment, a high proportion of FEP individuals may have been exposed to high plasma total triglyceride concentrations (up to 23%), low levels of HDL-C (23%), and a high total cholesterol/ HDL-C ratio (29%) [62] . 
ADDITIONAL RELEVANT ADVERSE EVENTS

Prolactin-Related Side Effects
Hyperprolactinemia is considered to be a disturbing adverse effect of antipsychotic medication, although recent investigations have described that it might be also a pre-existing or stress-related condition, since it has been described in antipsychotic-naïve clinical guidelines. In a previous finding, Agid et al. [128] described only a 20% responsiveness among subjects who did not respond to the first-line antipsychotic drug, whereas the efficacy rate of clozapine in these nonresponsive subjects was 75%; therefore early after a lack of response, a second antipsychotic trial and then the use of clozapine may be indicated when other issues such as adherence or co-morbidity have been addressed [27, 125] . Likely problems in switching antipsychotics in the treatment of schizophrenia such as the risk of discontinuation reactions and the re-emergence of psychotic symptoms have been traditionally described [129, 130] . Thus, overall patients should be monitored carefully throughout the switch procedure for any discontinuation effects or new side effects [131, 132] . More frequent contacts might be needed during the switching process in order to reassure the patient and to monitor for side effects and discontinuation problems [133, 134] . As with individuals with several episodes, using antipsychotic polypharmacy is discouraged due to a lack of proven efficacy and a higher risk of side effects [125, 135] .
Importantly, co-morbid symptoms such as depression, anxiety, suicide risk, and substance misuse must be correctly diagnosed and treated in order to avoid early refractoriness, lack of remission, and relapse [27, 125] . Subjects who not respond to the first antipsychotic trial after a few weeks have a low response rate thereafter.
Addressing co-morbidity must include not only choosing the appropriate antipsychotic medication but also offering adequate psychosocial interventions such as cognitive behavior therapy (CBT) or treating associated problems such as substance abuse [136, 137] . CBT has been reported as a useful treatment for schizophrenia in several reviews [138] [139] [140] [141] , particularly in the treatment of persistent positive symptoms as part of a combined therapy. This has led to the inclusion of CBT into services and recommendations of treatment guidelines for people suffering psychotic disorders, including a FEP [27, 125] . Moreover, CBT seems to be helpful in improving other symptoms such as negative symptoms, functioning, mood, and social anxiety [142] [143] [144] [145] . However, Jauhar et al.
described in a meta-analysis of CBT effectiveness for symptoms of schizophrenia that pooled effect sizes were in the ''small'' range for all the classes of symptoms considered (pooled effect size of -0.33 for overall symptoms; -0.25 for positive symptoms; negative sign favors CBT) [146] . Previous recent meta-analyses by Wykes et al. had described higher levels of effectiveness that were in any case modest (i.e., pooled effect size of -0.37 for positive symptoms, pooled effect size of -0.44 for negative symptoms) [147] . With regard to substance misuse, integrated CBT and motivational interviewing have been used with the aim of reducing the use of substances and reduce subsequent relapses in a FEP; however, results of these interventions are not clearly consistent [137, [148] [149] [150] . Although there are some ongoing trials evaluating the specific efficacy of CBT and motivational interviewing in reducing the use of some substances such as cannabis [151] , it is possible that the benefits of these psychosocial interventions are best reflected in their effects on symptomatic outcomes rather than in a reduction of substance use or relapse prevention, and therefore the appropriate strategy may be to address associated problems rather than the substance use per se [137] . CBT for psychosis (CBTp) cannot be considered as a global brand because not all approaches are the same. It is now highly recommended that choosing the most appropriate CBTp should take into account patient-defined goals and critical targets and the types of individuals who can benefit from therapy [152] .
How Long Should Patients be Maintained on Antipsychotic Medication After
Recovering from a First Episode?
In clinical practice, due to the lack of insight into the prophylactic effects of drugs, emergence of disturbing side effects, and concerns over the long-term harm associated with antipsychotics, it is unlikely that patients will accept an indefinite treatment after a single episode of psychosis [20] . However, stopping antipsychotic medication has been repeatedly demonstrated as the biggest predictor of relapse after a first episode [153] [154] [155] . Wunderink et al. [156] , exploring people that remitted after a FEP, observed that relapse rates were two times higher in individuals who gradually tapered or discontinued medication and only 20% of subjects could be successfully discontinued. Strikingly, those patients with an earlier reduction or discontinuation treatment strategy appear to have long-term functional gains compared with individuals who maintained treatment [157, 158] . In a recent investigation, Mayoral-van Son et al. 
What Else Can Clinicians do to Increase
Treatment Adherence during Early Phases of the Illness?
Independent of the initial high response rate after a FEP, during follow-up of the illness, the relapse rates are high, being up to 83% 5 years after the FEP [153] . Persistent substance use disorder, carer criticism, poorer premorbid adjustment, and, particularly, medication nonadherence (a fourfold risk) may significantly increase the risk for relapse in FEP [161] . In a previous report analyzing a subsample of 140 first episode individuals, we observed a similar relapse rate of 65% at 3 years after the first break of the illness, being adherence to antipsychotic treatment the only significant predictor for relapse [155] . Therefore, in order to prevent relapse, the best way would be to improve adherence and to reduce other symptoms to a severity of mild or less, but also a minimum duration time for this remission of 6 months, and has been used in FEP. Rates of remission vary widely in different studies and most of them do not provide duration criteria [173] . As an example, after a 1-year follow-up, only 31% of the initial subjects enrolled in the PAFIP program achieved remission [174] , in particular due to persistence of negative symptoms or to relapse in the last 6 months, which seem to be related to duration of untreated psychosis and premorbid functioning. Remission is closely related to functional recovery, although symptomatic remission rates tend to exceed functional recovery rates [173] . The best ways to achieve remission after improving initial symptoms seem to be preventing relapses and also detecting and treating secondary negative symptoms as early as possible. Additionally, vocational interventions have been recognized to be beneficial to achieve better functional outcomes [175] .
What Can we do to Help and Support Families and Caregivers of Individuals
Dealing with a First Episode?
One of the main objectives of FEP programs and early intervention services is to engage with both people with psychosis and their family and to facilitate support. However, until recently, most of the effort has gone into studying, recognizing, and reducing expressed emotion (EE) and its components -critical comments (CC) and emotional over-involvement (EOI) -due to its potential prediction of relapse and symptom exacerbation in schizophrenia. Given that a large majority of people during their FEP live at home with their families, these informal caregivers are affected by a stress-appraisal-coping framework [176] . This would mean that the extent to which the stressors are related to the relative's or caregiver's negative health is related to his/her appraisal (or subjective evaluation) of the stressor and his/her ability to cope with them. Apart from family interventions, basically aimed at preventing or reducing relapses, psychoeducation and support groups have been developed to improve the experience of caring for people with mental illness, and particularly may be recommended to families and caregivers of people with FEP and severe mental disorders [177] . The role of FEP programs and early intervention services is to detect the needs of the families and caregivers and give sustained appropriate communication and support, in order to improve their experience of caring and reduce associated stress.
New Second Generation Antipsychotics:
Future Options for First-episode Treatment
Although the antidopaminergic mechanism (need for D2R blockade) is still essential in the development of new antipsychotics, the investigation of new atypical antipsychotics has focused on either compounds with a broader spectrum of clinical benefits through dual dopaminergic and serotoninergic properties -''serotonin-dopamine activity modulators''-(e.g., partial agonism of D2R with enhanced affinity for specific serotonin receptor analog of aripiprazole) or exploiting less examined mechanisms (e.g., cholinergic, histaminergic, GABAergic, modulation of glutamate); for a review see Zajdel et al. [178] . Brexpiprazole, with structure, properties and uses that are most similar to those of aripiprazole, has recently exhibited good tolerability, with a lower incidence of akathisia than aripiprazole [179] . Initial animal studies with cariprazine, a potent D3/D2 receptor partial agonist with favored binding to D3 receptors, seem to point out it could be a better treatment option for patients with persistent and predominant negative symptoms [180] . The long half-life of cariprazine's principal active metabolites and the steady-state levels of cariprazine and metabolites within 4 weeks are pharmacological characteristics that may minimize the impact of missing doses on plasma levels [181] . Significant improvement in hostility has been also observed in cariprazine-versus placebo-treated patients [182] . Iloperidone shares a high affinity for both D2 and 5HT2A receptors, with a unique receptor-binding profile that includes a very strong affinity for the noradrenergic alpha 1 (NEa1) receptor [183] . It is a well-tolerated antipsychotic with a very low propensity to cause either akathisia or antipsychotic-induced extrapyramidal symptoms [184] . Lurasidone exerts a potent antagonism toward the dopamine D2, and the 5-hydroxytryptamine 
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